TNF signaling in vascular endothelial cells

Experimental and Molecular Pathology

Volumn 70, Issue 3, 2001, Pages 317-325

  Madge, Lisa A ^a   Pober, Jordan S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; SPHINGOMYELIN PHOSPHODIESTERASE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; CELL SPECIFICITY; CELL TYPE; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

EID: 0034964508     PISSN: 00144800     EISSN: None     Source Type: Journal    
DOI: 10.1006/exmp.2001.2368     Document Type: Article

References (86)

1. Induction of stress-activated protein kinases/c-Jun N-terminal kinases by the p55 tumour necrosis factor receptor does not require sphingomyelinases
2. A novel cytoplasmic domain of the p55 tumor necrosis factor receptor initiates the neutral sphingomyelinase pathway
3. FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase
4. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα
5. Tyr-716 in the platelet-derived growth factor beta-receptor kinase insert is involved in GRB2 binding and Ras activation
6. Accommodation of vascularized xenografts: Expression of "protective genes" by donor endothelial cells in a host Th2 cytokine environment
7. Tumor necrosis factor (TNF)-alpha activates c-raf-1 kinase via the p55 TNF receptor engaging neutral sphingomyelinase
8. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells
9. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death
10. Four different classes of inhibitors of receptor-mediated endocytosis decrease tumor necrosis factor-induced gene expression in human endothelial cells
11. Disparate localization of 55-kd and 75-kd tumor necrosis factor receptors in human endothelial cells
12. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor
13. Regulation of cell death protease caspase-9 by phosphorylation
14. Phosphoinositide kinases
15. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling
16. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
17. Kinase regulation in inflammatory response
18. Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation
19. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD
20. Cavedin-1 associates with Traf 2 to form a complex that is recruited to Tumor Necrosis Factor recepters
21. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3, 4-bisphosphate
22. Phosphoinositide kinases
23. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt
24. The death domain of tumor necrosis factor receptor 1 is necessary but not sufficient for Golgi retention of the receptor and mediates receptor desensitization
25. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor
26. Identification of Grb2 as a novel binding partner of tumor necrosis factor (TNF) receptor I
27. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex
28. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways
29. Role of cytochrome c and dATP/ATP hydrolysis in Apaf-1-mediated caspase-9 activation and apoptosis
30. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways
31. Inhibition of death receptor signals by cellular FLIP
32. Prevention of constitutive TNF receptor 1 signaling by silencer of death domains
33. A sustained reduction in IkappaB-beta may contribute to persistent NF-kappaB activation in human endothelial cells
34. TNF recruits TRADD to the plasma membrane but not the trans-Golgi network, the principal subcellular location of TNF-R1
35. JNK or IKK, AP-1 or NF-kappaB, which are the targets for MEK kinase 1 action?
36. Activation and homologous desensitization of human endothelial cells by CD40 ligand, tumor necrosis factor, and interleukin 1
37. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal
38. The C-terminal SH2 domain of p85 accounts for the high affinity and specificity of the binding of phosphatidylinositol 3-kinase to phosphorylated platelet-derived growth factor beta receptor
39. The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling
40. Acid sphingomyelinase is not essential for the IL-1 and tumor necrosis factor receptor signaling pathway leading to NFκB activation
41. Raf-1 activates MAP kinase-kinase
42. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE
43. Tumor necrosis factor is delivered to mitochondria where a tumor necrosis factor-binding protein is localized
44. The v-Src SH3 domain binds phosphatidylinositol 3′-kinase
45. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death
46. Human tumor necrosis factor alpha (TNF alpha) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors
47. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to Ras signaling
48. Bid, a Bc12 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors
49. A phosphatidylinositol 3-kinase/Akt pathway, activated by tumor necrosis factor or interleukin-1, inhibits apoptosis but does not activate NFkappaB in human endothelial cells
50. Apoptosis-inducing agents cause rapid shedding of tumor necrosis factor receptor 1 (TNFR1): A nonpharmacological explanation for inhibition of TNF-mediated activation
51. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex
52. TNF initiates E-selectin transcription in human endothelial cells through parallel TRAF-NF-kappa B and TRAF-RAC/CDC42-JNK-c-Jun/ATF2 pathways
53. Endothelial cell inflammatory responses to tumor necrosis factor alpha: Ceramide-dependent and -independent mitogen-activated protein kinase cascades
54. An induced proximity model for caspase-8 activation
55. MAP kinase activator from insulin-stimulated skeletal muscle is a protein threonine/tyrosine kinase
56. Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway
57. ASK1 is essential for JNK/SAPK activation by TRAF2
58. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase
59. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction
60. Activation and injury of endothelial cells by cytokines
61. Cytokines and endothelial cell biology
62. Involvement of Shc in insulin- and epidermal growth factor-induced activation of p21ras
63. Tumor necrosis factor alpha-induced activation of c-jun N-terminal kinase is mediated by TRAF2
64. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling
65. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt
66. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells
67. Inhibition of receptor internalization by monodansylcadaverine selectively blocks p55 tumor necrosis factor receptor death domain signaling
68. TNF-induced activation of NF-kappaB
69. Activation of stress-activated protein kinase/c-Jun N-terminal kinase, but not NF-kappaB, by the tumor necrosis factor (TNF) receptor 1 through a TNF receptor-associated factor 2- and germinal center kinase related-dependent pathway
70. Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis factor receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration
71. Ceramide is not a signal for tumor necrosis factor-induced gene expression but does cause programmed cell death in human vascular endothelial cells
72. Evidence that tumor necrosis factor triggers apoptosis in human endothelial cells by interleukin-1-converting enzyme-like protease-dependent and -independent pathways
73. A functional role of IkappaB-epsilon in endothelial cell activation
74. Nuclear factor (NF)-kappaB-regulated X-chromosome-linked lap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis
75. Ligand passing: The 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor
76. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis
77. The SH3 domain of p561ck is involved in binding to phosphatidylinositol 3′-kinase from T lymphocytes
78. Tumor necrosis factor receptor and Fas signaling mechanisms
79. NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
80. Requirement of FADD for tumor necrosis factor-induced activation of acid sphingomyelinase
81. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src
82. A role for c-Raf kinase and Ha-Ras in cytokine-mediated induction of cell adhesion molecules
83. Phosphorylation of Raf by ceramide-activated protein kinase
84. Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice
85. Tumor necrosis factor signaling to stress-activated protein kinase (SAPK)/Jun NH2-terminal kinase (JNK) and p38. Germinal center kinase couples TRAF2 to mitogen-activated protein kinase/ERK kinase 1 and SAPK while receptor interacting protein associates with a mitogen-activated protein kinase upstream of MKK6 and p38
86. Phosphorylation and regulation of Raf by Akt (protein kinase B)